Shire
Shire Wins FDA Approval for Motegrity for CIC
Motegrity, a selective serotonin-4 (5-HT4) receptor agonist, works by enhancing colonic peristalsis to increase ...
DECEMBER 20, 2018
FDA Approves Takhzyro for Rare Hereditary Angioedema
Takhzyro is the first monoclonal antibody approved in the United States to prevent attacks of hereditary angioedema ...
AUGUST 27, 2018
New Indication Granted for Adynovate
Adynovate can now be used for children younger than 12 years of age.
DECEMBER 27, 2016
Load more